Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Justus Bingham"'
Autor:
Richard T. Kenney, John K. Cini, Susan Dexter, Manuel DaFonseca, Justus Bingham, Isabelle Kuan, Sant P. Chawla, Thomas M. Polasek, Jason Lickliter, Philip J. Ryan
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe benefits of recombinant interleukin-12 (rIL-12) as a multifunctional cytokine and potential immunotherapy for cancer have been sought for decades based on its efficacy in multiple mouse models. Unexpected toxicity in the first phase 2 s
Externí odkaz:
https://doaj.org/article/9baead1eb8e549ccaed6f20a613f9c70
Autor:
Sant P. Chawla, Victoria S. Chua, Erlinda M. Gordon, John Cini, Susan Dexter, Manual DaFonseca, Justus Bingham, Grantham W. Hogeland, Richard T. Kenney
Publikováno v:
Cancer Research. 83:CT245-CT245
Recombinant interleukins (IL) have had limited clinical success due to inefficient tumor targeting and short pharmacokinetics (PK), requiring frequent dosing that leads to aberrant immunostimulation and toxicity. IL-12 is a promising cancer treatment
Autor:
Julia Zack, Justus Bingham, Peter Staehr, Xuegong Wang, Yu L. Ho, Luiz Belardinelli, Arvinder Dhalla
Publikováno v:
The Journal of Clinical Pharmacology. 53:385-392
GS-9667, a new selective, partial agonist of the A(1) adenosine receptor (AR), may represent an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA). The objectives of the studies were to evaluate the e
Autor:
Peter M, Staehr, Arvinder K, Dhalla, Julia, Zack, Xuegong, Wang, Yu L, Ho, Justus, Bingham, Luiz, Belardinelli
Publikováno v:
Journal of clinical pharmacology. 53(4)
GS-9667, a new selective, partial agonist of the A(1) adenosine receptor (AR), may represent an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA). The objectives of the studies were to evaluate the e
Publikováno v:
B58. TREATMENT OF PULMONARY ARTERIAL HYPERTENSION.
Publikováno v:
B58. TREATMENT OF PULMONARY ARTERIAL HYPERTENSION.